Erg6 LD de-localization correlates with altered TG:SE ratios and LCL-LD formation. (A) Yeast expressing Erg6-mNg and stained for LDs (MDH) at time points when yeasts were transferred from log-phase (2% glucose) to AGR. Red arrows indicate protein targeting. (B) TLC measurements of TG and SE in AGR-treated yeast over time. (C) Yeast expressing Erg6-mNg and MDH-stained for LDs. Yeast were either treated with AGR, AGR + lovastatin (sterol synthesis inhibitor) together, or AGR + Mg132 (proteasome inhibitor) together for 4 h. (D) Relative Manders M1 coefficient of Erg6-mNg colocalization with MDH LD stain in various conditions related to C. (E) TLC measurements of TG and SE from yeast treated for 4 h with AGR or AGR + lovastatin. (F) Yeast expressing Erg6-mNg and MDH-stained for LDs in log-phase (2% glucose), AGR, AGR + 0.1% OA, and AGR + 15 min 40°C. (G) Relative Manders M1 coefficient of Erg6-mNg colocalization with LD stain MDH in various conditions from F. (H) Time-lapse imaging of Erg6-mNg yeast stained with MDH, and heated up to 40°C following 4 h AGR. (I) Pln1(Pet10)-mNg in log and 4 h AGR. (J) Relative M1 coefficient of Pln1-mNG with LD targeting. Statistics are one-way ANOVA. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Scale bars, 5 μm.